Between 2012 and 2016, Eli Lilly and Company spent, on average, $8 million per year on lobbying the federal government.[i]

Biotechnology Innovation Organization (BIO).

Eli Lilly and Company is a leader of the pharmaceutical industry trade group the Biotechnology Innovation Organization (BIO).

During Azar’s tenure as President of Lilly USA, LLC, he served on the Executive Committee of BIO’s Board of Directors and Chairman of BIO’s Reimbursement Committee,[ii] which focuses on “health reform and reimbursement issues from a variety of perspectives, including legislative, regulatory, economic, marketing, and public relations. Members of the committee meet routinely with government officials regarding legislation and agency matters.”[iii]

In 2017, BIO has spent $7.03 million lobbying the federal government.[iv]

Pharmaceutical Researchers and Manufacturers of America (PhRMA)

Eli Lilly and Company is also a leader of the pharmaceutical industry trade group the Pharmaceutical Researchers and Manufacturers of America (PhRMA).

From 2012-2013, Eli Lilly and Company President and CEO John Lechleiter chaired PhRMA’s Board of Directors.[v] Current Eli Lilly and Company President and CEO Dave Ricks serves on the Board, and he was one of six board members who accompanied PhRMA CEO Steven Ubl to an Oval Office meeting with President Trump earlier this year.[vi]

In 2017, PhRMA has spent $19.8 million lobbying the federal government.[vii]

Drug Price Transparency Bills


Nevada

On June 15, 2017, Nevada Governor Brian Sandoval signed the bipartisan Senate Bill 539, which provides for transparency on diabetes drug prices.[viii]

During the legislative session, Lilly hired 5 lobbyists to work on its behalf, BIO hired 5 lobbyists, and PhRMA hired 7 lobbyists in Carson City.[ix]

California

On October 9, 2017, after a two-year campaign, California Governor Jerry Brown signed the bipartisan Senate Bill 17, which provides for transparency on prescription drug prices.[x]

In lobbying the California legislature between January 2015 and July 2017, Eli Lilly and Company spent $306,244, BIO spent $385,400 and PhRMA spent $1,904,375.[xi]


[i] Eli Lilly & Co., Center for Responsive Politics, https://www.opensecrets.org/orgs/summary.php?id=D000000166.
Data for 2012 – 2017 accessed October 31, 2017.
[ii] Alex M. Azar Bio, http://www.wwsg.com/speakers/alex-m-azar-ii/; also http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-speakers-list-2016.pdf.
[iii] https://www.bio.org/sites/default/files/Committee%20List%20Expanded%205%202016_web.pdf.
[iv] https://www.opensecrets.org/lobby/clientsum.php?id=D000024369. This figure is through October 21, 2017.
[v] http://www.phrma.org/press-release/lilly-s-john-lechleiter-becomes-phrma-board-chairman.
[vi] Tracy Staton, “Trump’s pharma CEO confab: Get prices ‘way down,’ get ‘better innovation’ and get back to U.S.,” FiercePharma, January 31, 2017, http://www.fiercepharma.com/pharma/novartis-phrma-ceos-to-face-trump-and-his-drug-pricing-vows-at-tuesday-meeting.
[vii] Open Secrets, “Pharmaceutical Research & Manufacturers of America: Client Profile: Summary, 2017,” The Center for Responsive Politics, accessed November 5, 2017,  https://www.opensecrets.org/lobby/clientsum.php?id=D000000504&year=2017.  This figure is through October 21, 2017.
[viii] Nevada Legislative Council Bureau, “Overview: Senate Bill 539,” accessed November 5, 2017, https://www.leg.state.nv.us/App/NELIS/REL/79th2017/Bill/5822/Overview.
[ix] Megan Messerly, “Pharmaceutical companies stock up on lobbyists as Democrats push bills targeting industry,” The Nevada Independent, April 10, 2017, https://thenevadaindependent.com/article/pharmaceutical-companies-stock-lobbyists-democrats-push-bills-targeting-industry.
[x] Melanie Mason, “Californians will get more information on what’s driving prescription drug prices under law signed by governor,” LA Times, October 9, 2017, http://beta.latimes.com/politics/la-pol-ca-prescription-drug-price-disclosure-20171009-story.html.
[xi] UNITE HERE original research; all data from the California Secretary of State, http://cal-access.sos.ca.gov/.